Press Releases

Date Title
Toggle Summary vTv Therapeutics Announces Common Stock Purchase Agreement for up to $47 Million with Lincoln Park Capital
HIGH POINT, N.C. , Nov. 24, 2020 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc.  (Nasdaq: VTVT) today announced it has entered into a common stock purchase agreement (“Purchase Agreement”) for up to $47 million with Lincoln Park Capital Fund, LLC (“LPC”), a Chicago -based institutional investor.
View HTML
Toggle Summary vTv Therapeutics Announces 2020 Third Quarter Financial Results and Update
HIGH POINT, N.C. , Nov. 05, 2020 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq:VTVT) today reported financial results for the third quarter ended September 30, 2020 , and provided an update on the progress of its clinical programs. “Following our decision to conclude enrollment in the Elevage
View HTML
Toggle Summary vTv Therapeutics Presents Baseline Characteristics of the Enrolled Subjects in the Elevage Study Suggesting Comparability to the Post-Hoc Diabetes Subgroup of the Phase 3 STEADFAST Study
HIGH POINT, N.C. , Nov. 04, 2020 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc.  (Nasdaq: VTVT) today reported baseline characteristics for the enrolled subjects in the ongoing Elevage clinical study of azeliragon as a potential treatment for mild Alzheimer’s disease (AD) in people with type 2 diabetes
View HTML
Toggle Summary vTv Therapeutics to Present Study Update and Preliminary Data on Baseline Characteristics of Study Participants in Phase 2 Elevage Study Evaluating Azeliragon at 13th Clinical Trials on Alzheimer’s Disease (CTAD) Digital Event
HIGH POINT, N.C. , Oct. 29, 2020 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc.  (Nasdaq: VTVT) today announced that it will make an oral presentation at the 13 th Clinical Trials on Alzheimer’s Disease (CTAD) Digital Event on November 4, 2020 . The presentation will provide a general study update and
View HTML
Toggle Summary vTv Therapeutics Presents Additional Positive Clinical Study Results Supporting the Safety and Efficacy of TTP399 as Adjunctive Therapy in Patients with Type 1 Diabetes
Data Reported at EASD Virtual Conference Demonstrate that TTP399 Did Not Increase Plasma or Urine Ketones, Avoiding a Key Limitation to the Development of Oral Adjunctive Therapies for T1D HIGH POINT, N.C. , Sept. 23, 2020 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc.
View HTML
Toggle Summary vTv Therapeutics to Present Additional Positive Clinical Study Results from Phase 2 Simplici-T1 Study of TTP399 as Adjunctive Therapy for Patients with Type 1 Diabetes at EASD Virtual Meeting
Potential First-in-Class, Liver-Selective Glucokinase Activator HIGH POINT, N.C. , Sept. 16, 2020 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc.  (Nasdaq: VTVT) today announced it will deliver two oral presentations emphasizing the potential of TTP399 as an oral adjunctive therapy in type 1 diabetes at
View HTML
Toggle Summary vTv Therapeutics Announces Appointment of Edward P. Taibi to its Board of Directors
HIGH POINT, N.C. , Sept. 15, 2020 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc.  (Nasdaq: VTVT) announced the appointment of Edward P. Taibi , Executive Vice President of MacAndrews & Forbes Incorporated (“MacAndrews”), to the vTv Board of Directors. Effective August 31, 2020 , Mr.
View HTML
Toggle Summary vTv Therapeutics Announces 2020 Second Quarter Financial Results and Update
HIGH POINT, N.C. , Aug. 03, 2020 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq:VTVT) today reported financial results for the second quarter ended June 30, 2020 , and provided an update on the progress of its clinical programs. “Building on the successful phase 2 study completed earlier this
View HTML
Toggle Summary vTv Therapeutics to Present Additional Clinical Data from the STEADFAST Study of Azeliragon at the Virtual Alzheimer's Association International Conference
HIGH POINT, N.C. , July 27, 2020 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc . (Nasdaq: VTVT) today announced that the Company will present at the upcoming 2020 Alzheimer's Association International Conference (AAIC), held virtually, July 27–31, 2020. The poster presentation will highlight additional
View HTML
Toggle Summary vTv Therapeutics Presents Two Late-Breaking Poster Sessions on Simplici-T1 Study at the American Diabetes Association’s Virtual Sessions Supporting the Potential of TTP399 as First-in-Class Oral Adjunctive Therapy for Type 1 Diabetes Patients
- Treatment with TTP399 resulted in significant improvements in HbA1c with reduction in insulin, without increasing risk of hypoglycemia or diabetic ketoacidosis (DKA) - HIGH POINT, N.C. , June 13, 2020 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc.  (Nasdaq: VTVT) today made two presentations at the
View HTML